<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631214</url>
  </required_header>
  <id_info>
    <org_study_id>20110142</org_study_id>
    <secondary_id>2011-003142-41</secondary_id>
    <nct_id>NCT01631214</nct_id>
  </id_info>
  <brief_title>Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis</brief_title>
  <acronym>ARCH</acronym>
  <official_title>A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment is effective in preventing fractures
      in women with postmenopausal osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, women were randomly assigned in a 1:1 ratio to receive monthly subcutaneous
      romosozumab or weekly oral alendronate for 12 months. Randomization was stratified according
      to age (&lt;75 vs. ≥75 years). After completion of the double-blind treatment period, all the
      participants were to receive open-label weekly oral alendronate until the end of the trial,
      with blinding to the initial treatment assignment maintained.

      The primary analysis was performed when clinical fracture events had been confirmed in at
      least 330 participants and all the participants had completed the month 24 visit. The study
      was to continue in an event-driven manner until at least 440 participants experienced a
      nonvertebral fracture or if the superiority of romosozumab was proven for nonvertebral
      fractures at the primary analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2012</start_date>
  <completion_date type="Actual">June 29, 2017</completion_date>
  <primary_completion_date type="Actual">February 27, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With New Vertebral Fractures Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>All fracture assessments were performed by blinded central imaging readers.
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Clinical Fracture at the Primary Analysis</measure>
    <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
    <description>All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis</measure>
    <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
    <description>A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Fracture at the Primary Analysis</measure>
    <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
    <description>All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis</measure>
    <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
    <description>Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Hip Fracture at the Primary Analysis</measure>
    <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
    <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Clinical Fracture Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Nonvertebral Fracture Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Hip Fracture Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Clinical Vertebral Fracture Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Clinical Fracture Through Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Vertebral Fractures Through Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Fracture Through Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Nonvertebral Fracture Through Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Hip Fracture Through Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Osteoporotic Fracture Through Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Clinical Vertebral Fracture Through Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36</measure>
    <time_frame>Baseline and month 36</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36</measure>
    <time_frame>Baseline and month 36</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36</measure>
    <time_frame>Baseline and month 36</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4093</enrollment>
  <condition>Postmenopausal Women With Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Alendronate/Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab/Alendronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.</description>
    <arm_group_label>Romosozumab/Alendronate</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>Evenity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Alendronate 70 mg tablet taken once a week</description>
    <arm_group_label>Alendronate/Alendronate</arm_group_label>
    <arm_group_label>Romosozumab/Alendronate</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Romosozumab</intervention_name>
    <description>Administered by subcutaneous injection once a month during the double-blind treatment phase.</description>
    <arm_group_label>Alendronate/Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Alendronate</intervention_name>
    <description>Matching placebo tablet taken once a week during the double-blind treatment phase.</description>
    <arm_group_label>Romosozumab/Alendronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Postmenopausal women who meet at least one of the following bone mineral density (BMD) and
        fracture criteria:

          -  BMD T-score at the total hip or femoral neck of ≤ -2.50 and EITHER:

               -  at least 1 moderate (semiquantitative grade [SQ]2) or severe (SQ3) vertebral
                  fracture OR

               -  at least 2 mild (SQ1) vertebral fractures OR

          -  BMD T-score at the total hip or femoral neck of ≤ -2.00 and EITHER:

               -  at least 2 moderate (SQ2) or severe (SQ3) vertebral fractures OR

               -  a fracture of the proximal femur that occurred within 3 to 24 months prior to
                  randomization.

        Exclusion Criteria:

          -  History of metabolic or bone disease (except osteoporosis)

          -  Use of agents affecting bone metabolism

          -  Vitamin D insufficiency

          -  History of solid organ or bone marrow transplants

          -  Hyper- or hypocalcemia

          -  Hyper- or hypothyroidism

          -  Hyper- or hypoparathyroidism

          -  Possible signs of intolerance to alendronate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Lake Tahoe</city>
        <state>California</state>
        <zip>96150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Angeles</city>
        <state>Washington</state>
        <zip>98362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1114</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1430CKE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600DHK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>X5000BNB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liège</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60115-282</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>71625-009</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vitória</city>
        <state>Espírito Santo</state>
        <zip>29055-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <state>Goiás</state>
        <zip>74070-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>52020-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1202</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1421</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1504</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westmout</city>
        <state>Quebec</state>
        <zip>H3Z 1E5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8350595</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlántico</state>
        <zip>08001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>11001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <zip>11001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucaramanga</city>
        <zip>68003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klatovy</city>
        <zip>339 38</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opava</city>
        <zip>746 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Trebovice</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Århus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Domingo</city>
        <state>Distrito Nacional</state>
        <zip>10124</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Domingo</city>
        <state>Distrito Nacional</state>
        <zip>10514</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>51000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Domingo</city>
        <zip>10605</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <zip>50410</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cahors Cedex</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cédex 3</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orleans Cedex</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin (Hellersdorf)</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heinsberg</city>
        <zip>52525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>14561</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>16673</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antigua</city>
        <state>Sacatepéquez</state>
        <zip>03001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01007</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01009</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01012</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01014</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01052</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1084</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiskunhalas</city>
        <zip>6400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bnei Brak</city>
        <zip>51108</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>71713</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91007</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>61999</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arenzano GE</city>
        <zip>16011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20145</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guri-si</city>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si, Gyeonggi-do</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liepaja</city>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vilnius</city>
        <zip>09310</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vilnius</city>
        <zip>10323</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California Norte</state>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexicalli</city>
        <state>Baja California Norte</state>
        <zip>21200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37520</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Queretaro</city>
        <state>Querétaro</state>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Obregon</city>
        <state>Sonora</state>
        <zip>85000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8022</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grafton, Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <zip>0050</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dabrowka Dopiewo</city>
        <zip>62-069</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <zip>25-317</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>09-245</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-558</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-356</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030463</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oradea</city>
        <zip>410028</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice-Saca</city>
        <zip>040 15</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piestany</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parow</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tygerberg</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sant Joan Despi</city>
        <state>Cataluña</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mölndal</city>
        <zip>431 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umeå</city>
        <zip>907 36</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 5GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chorley</city>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0FT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sidcup</city>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staffordshire</city>
        <zip>WS11 5XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warwick</city>
        <zip>CV34 5BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Dominican Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.</citation>
    <PMID>28892457</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <results_first_submitted>November 20, 2018</results_first_submitted>
  <results_first_submitted_qc>November 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2018</results_first_posted>
  <disposition_first_submitted>December 11, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>December 11, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 13, 2017</disposition_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis, Osteoporosis-postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01631214/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01631214/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 270 centers in 41 countries globally from 04 May 2012 to 29 June 2017.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1 ratio to receive romosozumab or alendronate for 12 months. Randomization was stratified by age (&lt; 75 vs. ≥ 75 years). After completion of the double-blind trial period, all participants received open-label alendronate until the end of the trial, with blinding to the initial treatment assignment maintained.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alendronate/Alendronate</title>
          <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
        </group>
        <group group_id="P2">
          <title>Romosozumab/Alendronate</title>
          <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2047"/>
                <participants group_id="P2" count="2046"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2040"/>
                <participants group_id="P2" count="2038"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Double-blind Period</title>
              <participants_list>
                <participants group_id="P1" count="1823"/>
                <participants group_id="P2" count="1831"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Primary Analysis Period</title>
              <participants_list>
                <participants group_id="P1" count="1576"/>
                <participants group_id="P2" count="1574"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1503"/>
                <participants group_id="P2" count="1523"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="544"/>
                <participants group_id="P2" count="523"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="290"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for Alternative Therapy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alendronate/Alendronate</title>
          <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
        </group>
        <group group_id="B2">
          <title>Romosozumab/Alendronate</title>
          <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2047"/>
            <count group_id="B2" value="2046"/>
            <count group_id="B3" value="4093"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.2" spread="7.5"/>
                    <measurement group_id="B2" value="74.4" spread="7.5"/>
                    <measurement group_id="B3" value="74.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2047"/>
                    <measurement group_id="B2" value="2046"/>
                    <measurement group_id="B3" value="4093"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="662"/>
                    <measurement group_id="B2" value="631"/>
                    <measurement group_id="B3" value="1293"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1385"/>
                    <measurement group_id="B2" value="1415"/>
                    <measurement group_id="B3" value="2800"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="286"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1415"/>
                    <measurement group_id="B2" value="1447"/>
                    <measurement group_id="B3" value="2862"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="446"/>
                    <measurement group_id="B2" value="436"/>
                    <measurement group_id="B3" value="882"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age Strata per Randomization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="976"/>
                    <measurement group_id="B2" value="973"/>
                    <measurement group_id="B3" value="1949"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1071"/>
                    <measurement group_id="B2" value="1073"/>
                    <measurement group_id="B3" value="2144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severe Vertebral Fracture</title>
          <description>A participant had a prevalent vertebral fracture if any vertebra from T4 to L4 had a grade of 3 at baseline based on an assessment of spinal radiographs using the Genant Semiquantitative Scoring Method. A grade 3 fracture is defined as approximately 40% or greater reduction in anterior, middle, and/or posterior height.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Presence</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1321"/>
                    <measurement group_id="B2" value="1369"/>
                    <measurement group_id="B3" value="2690"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absence</title>
                  <measurement_list>
                    <measurement group_id="B1" value="726"/>
                    <measurement group_id="B2" value="677"/>
                    <measurement group_id="B3" value="1403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Hip Bone Mineral Density (BMD) T-score</title>
          <description>BMD was measured using dual-energy x-ray absorptiometry (DXA). The T-score is a comparison of a person's bone density with that of a healthy 30-year-old of the same sex. Lower scores (more negative) mean lower bone density: A T-score of -2.5 or lower qualifies as osteoporosis and a T-score of -1.0 to - 2.5 signifies osteopenia, meaning below-normal bone density without full osteoporosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤ -2.5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1384"/>
                    <measurement group_id="B2" value="1356"/>
                    <measurement group_id="B3" value="2740"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; -2.5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="662"/>
                    <measurement group_id="B2" value="690"/>
                    <measurement group_id="B3" value="1352"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With New Vertebral Fractures Through Month 24</title>
        <description>All fracture assessments were performed by blinded central imaging readers.
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.</description>
        <time_frame>24 months</time_frame>
        <population>Randomized participants with a baseline and ≥ 1 postbaseline evaluation of vertebral fracture, including participants who had vertebrae with missing Genant semiquantitative scores at baseline whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Vertebral Fractures Through Month 24</title>
          <description>All fracture assessments were performed by blinded central imaging readers.
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.</description>
          <population>Randomized participants with a baseline and ≥ 1 postbaseline evaluation of vertebral fracture, including participants who had vertebrae with missing Genant semiquantitative scores at baseline whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1834"/>
                <count group_id="O2" value="1825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The primary endpoints were tested at the 5% level (2-sided), accounting for multiplicity using the Hochberg procedure. If the larger of the 2 p-values was significant at the 0.05 level (2-sided), the statistical testing continued to the secondary endpoint in the testing sequence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on a logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab. The standard error (SE) represents the standard error of log(odds ratio).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk ratio (ratio of percentages, Romosozumab:Alendronate) was based on the Mantel Haenszel method, adjusted for age strata (&lt;75 vs. ≥75 years), the presence or absence of severe vertebral fracture at baseline, and baseline bone mineral density T-score at the total hip (≤ -2.5, &gt; -2.5).
Values &lt; 1 for risk ratio favor romosozumab.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
            <estimate_desc>SE represents the standard error of log (risk ratio).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The absolute risk reduction (difference in percentages, Alendronate – Romosozumab) was based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score (≤ -2.5, &gt; -2.5), and presence of severe vertebral fracture at baseline.
Positive values for absolute risk reduction favor romosozumab.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Absolute risk reduction</param_type>
            <param_value>4.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.50</ci_lower_limit>
            <ci_upper_limit>5.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Clinical Fracture at the Primary Analysis</title>
        <description>All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
        <population>All randomized participants. Missing values for clinical fractures were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinical Fracture at the Primary Analysis</title>
          <description>All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>All randomized participants. Missing values for clinical fractures were imputed using last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The primary endpoints were tested at the 5% level (2-sided), accounting for multiplicity using the Hochberg procedure. If the larger of the 2 p-values was significant at the 0.05 level (2-sided), the statistical testing continued to the secondary endpoint in the testing sequence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis</title>
        <description>A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis</title>
          <description>A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>If the 2 primary endpoints and the specified BMD secondary endpoints were all significant, the nonvertebral fracture at the primary analysis was evaluated based on a 1-sided test (overall α=0.025) determined by the Lan-DeMets alpha spending function that approximates a Pocock boundary, 0.0233 (1-sided).</non_inferiority_desc>
            <p_value>0.040</p_value>
            <p_value_desc>The adjusted 2-sided p-value is reported.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Fracture at the Primary Analysis</title>
        <description>All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.</description>
        <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Fracture at the Primary Analysis</title>
          <description>All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24</title>
        <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.</description>
        <time_frame>24 months</time_frame>
        <population>Randomized participants with a baseline and ≥ 1 postbaseline evaluation of vertebral fracture, including participants who had vertebrae with missing Genant semiquantitative scores at baseline whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24</title>
          <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.</description>
          <population>Randomized participants with a baseline and ≥ 1 postbaseline evaluation of vertebral fracture, including participants who had vertebrae with missing Genant semiquantitative scores at baseline whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1834"/>
                <count group_id="O2" value="1825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab. The standard error (SE) represents the standard error of log(odds ratio).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk ratio (ratio of percentages, Romosozumab:Alendronate) was based on the Mantel Haenszel method, adjusted for age strata (&lt;75 vs. ≥75 years), the presence or absence of severe vertebral fracture at baseline, and baseline bone mineral density T-score at the total hip (≤ -2.5, &gt; -2.5).
Values &lt; 1 for risk ratio favor romosozumab.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
            <estimate_desc>SE represents the standard error of log (risk ratio).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The absolute risk reduction (difference in percentages, Alendronate – Romosozumab) was based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score (≤ -2.5, &gt; -2.5), and presence of severe vertebral fracture at baseline.
Positive values for absolute risk reduction favor romosozumab.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Absolute risk reduction</param_type>
            <param_value>4.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.80</ci_lower_limit>
            <ci_upper_limit>6.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis</title>
        <description>Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
        <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis</title>
          <description>Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Hip Fracture at the Primary Analysis</title>
        <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
        <time_frame>The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hip Fracture at the Primary Analysis</title>
          <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.015</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24</title>
        <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.</description>
        <time_frame>24 months</time_frame>
        <population>Randomized participants with a baseline and ≥ 1 postbaseline evaluation of vertebral fracture, including participants who had vertebrae with missing Genant semiquantitative scores at baseline whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24</title>
          <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.</description>
          <population>Randomized participants with a baseline and ≥ 1 postbaseline evaluation of vertebral fracture, including participants who had vertebrae with missing Genant semiquantitative scores at baseline whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1834"/>
                <count group_id="O2" value="1825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.008</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab. The standard error (SE) represents the standard error of log(odds ratio).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk ratio (ratio of percentages, Romosozumab:Alendronate) was based on the Mantel Haenszel method, adjusted for age strata (&lt;75 vs. ≥75 years), the presence or absence of severe vertebral fracture at baseline, and baseline bone mineral density T-score at the total hip (≤ -2.5, &gt; -2.5).
Values &lt; 1 for risk ratio favor romosozumab.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>SE represents the standard error of log (risk ratio).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The absolute risk reduction (difference in percentages, Alendronate – Romosozumab) was based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score (≤ -2.5, &gt; -2.5), and presence of severe vertebral fracture at baseline.
Positive values for absolute risk reduction favor romosozumab.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Absolute risk reduction</param_type>
            <param_value>1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Clinical Fracture Through Month 24</title>
        <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>24 months</time_frame>
        <population>All randomized participants; Missing values for clinical fractures were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinical Fracture Through Month 24</title>
          <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>All randomized participants; Missing values for clinical fractures were imputed using last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.005</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Nonvertebral Fracture Through Month 24</title>
        <description>A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>24 months</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Nonvertebral Fracture Through Month 24</title>
          <description>A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.074</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Hip Fracture Through Month 24</title>
        <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
        <time_frame>24 months</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hip Fracture Through Month 24</title>
          <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.17</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Clinical Vertebral Fracture Through Month 24</title>
        <description>A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.</description>
        <time_frame>24 months</time_frame>
        <population>All randomized participants; Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinical Vertebral Fracture Through Month 24</title>
          <description>A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.</description>
          <population>All randomized participants; Last observation carried forward imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Clinical Fracture Through Month 12</title>
        <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>12 months</time_frame>
        <population>All randomized participants; Missing values for clinical fractures were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinical Fracture Through Month 12</title>
          <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>All randomized participants; Missing values for clinical fractures were imputed using last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.027</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Vertebral Fractures Through Month 12</title>
        <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader.</description>
        <time_frame>12 months</time_frame>
        <population>Randomized participants with a baseline and ≥ 1 postbaseline evaluation of vertebral fracture, including participants who had vertebrae with missing Genant semiquantitative scores at baseline whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Vertebral Fractures Through Month 12</title>
          <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Incident vertebral fractures were confirmed by a second independent reader.</description>
          <population>Randomized participants with a baseline and ≥ 1 postbaseline evaluation of vertebral fracture, including participants who had vertebrae with missing Genant semiquantitative scores at baseline whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1703"/>
                <count group_id="O2" value="1696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.008</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on a logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab. The standard error (SE) represents the standard error of log(odds ratio).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk ratio (ratio of percentages, Romosozumab:Alendronate) was based on the Mantel Haenszel method, adjusted for age strata (&lt;75 vs. ≥75 years), the presence or absence of severe vertebral fracture at baseline, and baseline bone mineral density T-score at the total hip (≤ -2.5, &gt; -2.5).
Values &lt; 1 for risk ratio favor romosozumab.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
            <estimate_desc>SE represents the standard error of log (risk ratio).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The absolute risk reduction (difference in percentages, Alendronate – Romosozumab) was based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score (≤ -2.5, &gt; -2.5), and presence of severe vertebral fracture at baseline.
Positive values for absolute risk reduction favor romosozumab.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Absolute risk reduction</param_type>
            <param_value>1.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>3.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Fracture Through Month 12</title>
        <description>All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.</description>
        <time_frame>12 months</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Fracture Through Month 12</title>
          <description>All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Nonvertebral Fracture Through Month 12</title>
        <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>12 months</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Nonvertebral Fracture Through Month 12</title>
          <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.057</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Hip Fracture Through Month 12</title>
        <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
        <time_frame>12 months</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hip Fracture Through Month 12</title>
          <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.19</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Osteoporotic Fracture Through Month 12</title>
        <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>12 months</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Major Osteoporotic Fracture Through Month 12</title>
          <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.053</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Clinical Vertebral Fracture Through Month 12</title>
        <description>A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.</description>
        <time_frame>12 months</time_frame>
        <population>All randomized participants; Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinical Vertebral Fracture Through Month 12</title>
          <description>A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.</description>
          <population>All randomized participants; Last observation carried forward imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2047"/>
                <count group_id="O2" value="2046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>0.14</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model adjusted for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
Hazard ratio &lt; 1 favors romosozumab; SE represents the standard error of log (hazard ratio).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 24</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1577"/>
                <count group_id="O2" value="1571"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="0.2"/>
                    <measurement group_id="O2" value="15.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an analysis of covariance (ANCOVA) model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.58</ci_lower_limit>
            <ci_upper_limit>8.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 24</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1627"/>
                <count group_id="O2" value="1622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.1"/>
                    <measurement group_id="O2" value="7.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an ANCOVA model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.42</ci_lower_limit>
            <ci_upper_limit>4.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 24</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1627"/>
                <count group_id="O2" value="1622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.2"/>
                    <measurement group_id="O2" value="6.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an ANCOVA model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.40</ci_lower_limit>
            <ci_upper_limit>4.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1718"/>
                <count group_id="O2" value="1722"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.1"/>
                    <measurement group_id="O2" value="13.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an ANCOVA model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.31</ci_lower_limit>
            <ci_upper_limit>9.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1781"/>
                <count group_id="O2" value="1781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.1"/>
                    <measurement group_id="O2" value="6.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an ANCOVA model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.03</ci_lower_limit>
            <ci_upper_limit>3.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1781"/>
                <count group_id="O2" value="1781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.1"/>
                    <measurement group_id="O2" value="4.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an ANCOVA model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.90</ci_lower_limit>
            <ci_upper_limit>3.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 36</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1597"/>
                <count group_id="O2" value="1593"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="0.2"/>
                    <measurement group_id="O2" value="15.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an ANCOVA model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>7.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.84</ci_lower_limit>
            <ci_upper_limit>7.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 36</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1653"/>
                <count group_id="O2" value="1653"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.1"/>
                    <measurement group_id="O2" value="7.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an ANCOVA model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.29</ci_lower_limit>
            <ci_upper_limit>4.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 36</time_frame>
        <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate/Alendronate</title>
            <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Alendronate</title>
            <description>Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>All randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1653"/>
                <count group_id="O2" value="1653"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.2"/>
                    <measurement group_id="O2" value="6.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparisons of the percent change from baseline in bone mineral density were analyzed using an ANCOVA model adjusted for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.18</ci_lower_limit>
            <ci_upper_limit>3.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Double-blind treatment phase: 12 months. Overall study period: From first dose of study drug up to the end of study for participants who received at any open-label dose and up to the end of the double-blind period for participants who did not. The median duration of follow-up time was 36 months.</time_frame>
      <desc>The safety analysis set included all randomized subjects who received ≥ 1 active dose of investigational product in the 12-month double-blind alendronate-controlled study period. Two participants randomized to alendronate received romosozumab in error and are counted in the romosozumab group for safety.
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double-blind Period: Alendronate 70 mg QW</title>
          <description>Participants received 70 mg alendronate once a week (QW) and placebo to romosozumab subcutaneously once a month for 12 months during the double-blind treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Double-blind Period: Romosozumab 210 mg QM</title>
          <description>Participants received 210 mg romosozumab subcutaneously once a month (QM) and placebo to alendronate orally once a week for the first 12 months during the double-blind treatment period.</description>
        </group>
        <group group_id="E3">
          <title>Overall Study: Alendronate / Alendronate</title>
          <description>Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.</description>
        </group>
        <group group_id="E4">
          <title>Overall Study: Romosozumab / Alendronate</title>
          <description>Participants received 210 romosozumab mg subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="278" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="262" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="638" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="611" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vestibular ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypercorticoidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Toxic goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Endocrine ophthalmopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Entropion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Retinal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vitreous prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Femoral hernia incarcerated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Mesenteric arterial occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Ampulla of Vater stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Biliary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Infected fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pancreas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ilium fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Subarachnoid haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Carcinoembryonic antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Coagulation time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Medical observation normal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Extraskeletal ossification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Fracture pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bladder squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Central nervous system neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Choroid melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Colorectal carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Epithelioid mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hepatobiliary cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intraductal papillary mucinous neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intraocular melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metastases to pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Myeloproliferative neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma unspecified histology indolent stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Retroperitoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of pharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Carotid aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Mixed dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Post-traumatic epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Stroke in evolution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Urethral polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Vocal cord cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Limb prosthesis user</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Loss of personal independence in daily activities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Labile hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Subclavian artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1190" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="1112" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="1498" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="1424" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="165" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="187" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="176" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="226" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="205" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="244" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="180" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="406" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="388" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="161" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="115" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="342" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="287" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="380" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="343" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="395" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="330" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="121" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="155" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="145" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="206" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="189" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="253" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="230" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="149" subjects_at_risk="2040"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="190" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="163" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="147" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="2014"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="2040"/>
                <counts group_id="E3" subjects_affected="232" subjects_at_risk="2014"/>
                <counts group_id="E4" subjects_affected="233" subjects_at_risk="2040"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

